^
    Back
    Association details:
    Biomarker:TP53 T175H + PIK3CA H1047R
    Cancer:Burkitt Lymphoma
    Drug:Zydelig (idelalisib) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Ann Hematol
    Title:

    Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation

    Published date:
    03/20/2020
    Excerpt:
    The successful salvage therapy with idelalisib in a patient with relapsed immunodeficiency-associated BL exhibiting a TP53 mutation and a H1047R mutation in the PIK3CA gene...off-label idelalisib was initiated (150 mg bid) inducing shrinkage of the tumor...Analysis of the initial lymphoma by high-throughput sequencing (HTS) detected a TP53 mutation (T175H, VAF 83.5%).
    DOI:
    10.1007/s00277-020-03974-y